ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
BioLineRx Doses First Patient in Solid Tumor Immunotherapy Study
September 27, 2019BioLineRx announced dosing of the first patient in part 2 of the Phase 1/2a clinical study for AGI-134, a novel compound that evokes a direct anti-tumor response, as well as a vaccine effect, via a unique ... -
BioLineRx Successfully Completes Dose-Escalation Part for AGI-134 Study
September 04, 2019BioLineRx has successfully completed the dose-escalation part of the Phase 1/2a clinical study for AGI-134, a novel compound that evokes a direct anti-tumor response, as well as a vaccine effect... -
BioLineRx Announces FDA Approval of IND Application for AGI-134
May 08, 2019BioLineRx announced the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application for AGI-134, a novel immunotherapy anti-cancer vaccine for solid tumors.
Pharma Sources Insight January 2025
